AI test targets abiraterone to prostate cancer patients

An AI test identifies prostate cancer patients who will benefit from the drug abiraterone, potentially extending their lives. The test analyzes tumor samples to predict which men with high-risk, non-spread prostate cancer will respond best to the treatment. The study, using data from the STAMPEDE trial, found abiraterone significantly reduced the risk of death for a specific group of men. The AI test helps identify those most likely to benefit, potentially avoiding unnecessary treatment and side effects for others. Researchers are urging NHS England to reconsider funding abiraterone for eligible patients, as the AI test allows for more precise targeting. The drug is currently available in Scotland and Wales, but not in England.